Shukra Pharmaceuticals Reports Mixed Financial Results Amid Growing Sales and Profit Concerns in June 2025

Shukra Pharmaceuticals, a microcap company in the Pharmaceuticals & Biotechnology sector, recently announced its financial results for the quarter ending June 2025. The evaluation changes reflect a notable shift in the company's score, which has moved to -1 from 1 over the past three months. The financial data reveals that net sales for the latest six months reached Rs 18.66 crore, demonstrating a year-on-year growth of 32.72%. This positive trend in sales indicates a robust demand for the company's products in the near term. However, the results also highlight challenges for Shukra Pharmaceuticals. The profit after tax (PAT) for the quarter was reported at Rs 1.03 crore, which represents a significant decline compared to the average PAT of Rs 2.40 crore from the previous four quarters. This downward trend in PAT raises concerns about the company's profitability. Additionally, non-operating income accounted for 81.02% of profit before tax, suggesting a reliance on income from non-business activities, which may not be sustainable in the long run. For more insights on Shukra Pharmaceuticals and its financial performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.